{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T01:13:38Z","timestamp":1773969218867,"version":"3.50.1"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T00:00:00Z","timestamp":1766534400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013017","name":"Vanderbilt University Medical Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013017","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007208","name":"Vanderbilt Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007208","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology Reports"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.gore.2025.102017","type":"journal-article","created":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T17:10:23Z","timestamp":1767028223000},"page":"102017","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Impact of carboplatin desensitization therapy on progression-free survival in gynecologic cancers"],"prefix":"10.1016","volume":"63","author":[{"given":"Nikita","family":"Bastin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Halle","family":"Petrie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amir","family":"Javid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robin","family":"Lane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taryn","family":"Boucher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alaina J.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauren S.","family":"Prescott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald D.","family":"Alvarez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Crispens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cosby A.","family":"Stone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.gore.2025.102017_b0005","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1007\/s00432-018-2753-y","article-title":"Impact of carboplatin hypersensitivity and desensitization on patients with recurrent ovarian cancer","volume":"144","author":"Altwerger","year":"2018","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.gore.2025.102017_b0010","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ygyno.2016.10.023","article-title":"Cisplatin can be safely administered to ovarian cancer patients with hypersensitivity to carboplatin","volume":"144","author":"Bergamini","year":"2017","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.gore.2025.102017_b0015","doi-asserted-by":"crossref","first-page":"199.e1","DOI":"10.1016\/j.ajog.2007.04.044","article-title":"Use of cisplatin without desensitization after carboplatin hypersensitivity reaction in epithelial ovarian and primary peritoneal cancer","volume":"197","author":"Callahan","year":"2007","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.gore.2025.102017_b0020","doi-asserted-by":"crossref","unstructured":"Caruso G, Weroha SJ, Cliby W. Ovarian Cancer: A Review. JAMA. Published online July 21, 2025. doi:10.1001\/jama.2025.9495.","DOI":"10.1001\/jama.2025.9495"},{"issue":"3","key":"10.1016\/j.gore.2025.102017_b0025","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.ygyno.2012.03.006","article-title":"BRCA1\/2 mutations and expression: Response to platinum chemotherapy in patients with advanced stage epithelial ovarian cancer","volume":"125","author":"Dann","year":"2012","journal-title":"Gynecol. Oncol."},{"issue":"7","key":"10.1016\/j.gore.2025.102017_b0030","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1200\/JCO-24-02589","article-title":"Neoadjuvant Chemotherapy for newly Diagnosed, Advanced Ovarian Cancer: ASCO Guideline Update","volume":"43","author":"Gaillard","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.gore.2025.102017_b0035","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1200\/JCO.1999.17.1.409","article-title":"Review of the Comparative Pharmacology and Clinical activity of Cisplatin and Carboplatin","volume":"17","author":"Go","year":"1999","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.gore.2025.102017_b0040","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.canlet.2015.08.028","article-title":"High response rates to neoadjuvant platinum-based therapy in ovarian cancer patients carrying germ-line BRCA mutation","volume":"369","author":"Gorodnova","year":"2015","journal-title":"Cancer Lett."},{"key":"10.1016\/j.gore.2025.102017_b0045","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.critrevonc.2016.03.014","article-title":"Cisplatin versus carboplatin: comparative review of therapeutic management in solid malignancies","volume":"102","author":"Ho","year":"2016","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"3","key":"10.1016\/j.gore.2025.102017_b0050","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.jaip.2024.12.021","article-title":"Risk Factors of Hypersensitivity Reactions to Carboplatin: a Systematic Review and Meta-Analysis","volume":"13","author":"Jang","year":"2025","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"10.1016\/j.gore.2025.102017_b0055","article-title":"Platinum desensitization therapy and its impact on the prognosis of ovary high-grade serous adenocarcinoma: a real world-data","volume":"15","author":"Li","year":"2024","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.gore.2025.102017_b0060","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1023\/A:1008215213739","article-title":"Carboplatin versus cisplatin in solid tumors: an analysis of the literature","volume":"9","author":"Lokich","year":"1998","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.gore.2025.102017_b0065","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ygyno.2014.01.042","article-title":"A systematic review comparing cisplatin and carboplatin plus paclitaxel-based chemotherapy for recurrent or metastatic cervical cancer","volume":"133","author":"Lorusso","year":"2014","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.gore.2025.102017_b0070","doi-asserted-by":"crossref","unstructured":"Lu KH, Broaddus RR. Endometrial Cancer. Longo DL, ed. N Engl J Med. 2020;383(21):2053-2064. doi:10.1056\/NEJMra1514010.","DOI":"10.1056\/NEJMra1514010"},{"issue":"1","key":"10.1016\/j.gore.2025.102017_b0075","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.ygyno.2019.04.013","article-title":"Platinum single-agent vs. platinum-based doublet agent concurrent chemoradiotherapy for locally advanced cervical cancer: a meta-analysis of randomized controlled trials","volume":"154","author":"Ma","year":"2019","journal-title":"Gynecol. Oncol."},{"issue":"24","key":"10.1016\/j.gore.2025.102017_b0080","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1056\/NEJMoa1813181","article-title":"Adjuvant Chemotherapy plus Radiation for locally Advanced Endometrial Cancer","volume":"380","author":"Matei","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.gore.2025.102017_b0085","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.21873\/invivo.11702","article-title":"Readministration of platinum Agents in Recurrent Ovarian Cancer patients who developed Hypersensitivity Reactions to Carboplatin","volume":"33","author":"Narui","year":"2019","journal-title":"In Vivo"},{"issue":"2","key":"10.1016\/j.gore.2025.102017_b0090","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.ygyno.2006.04.002","article-title":"Evaluation of the incidence of carboplatin hypersensitivity reactions in cancer patients","volume":"103","author":"Navo","year":"2006","journal-title":"Gynecol. Oncol."},{"issue":"4","key":"10.1016\/j.gore.2025.102017_b0095","first-page":"3465","article-title":"Safety of cisplatin after severe hypersensitivity reactions to carboplatin in patients with recurrent ovarian carcinoma","volume":"23","author":"Ottaiano","year":"2003","journal-title":"Anticancer Res"},{"issue":"45","key":"10.1016\/j.gore.2025.102017_b0100","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000031726","article-title":"Toxicity management and efficacy of carboplatin desensitization therapy for recurrent epithelial ovarian carcinoma: a real-world study","volume":"101","author":"Paksoy","year":"2022","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"10.1016\/j.gore.2025.102017_b0105","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1158\/1078-0432.CCR-13-2287","article-title":"Germline and Somatic Mutations in Homologous Recombination Genes Predict platinum Response and Survival in Ovarian, Fallopian Tube, and Peritoneal Carcinomas","volume":"20","author":"Pennington","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.gore.2025.102017_b0110","doi-asserted-by":"crossref","first-page":"800","DOI":"10.3389\/fphar.2017.00800","article-title":"Risk Factors of Hypersensitivity to Carboplatin in patients with Gynecologic Malignancies","volume":"8","author":"Tai","year":"2017","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.gore.2025.102017_b0115","article-title":"Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA -Related Cancer: US Preventive Services Task Force Recommendation Statement","volume":"322(7):652","author":"US Preventive Services Task Force","year":"2019","journal-title":"J. Am. Med. Assoc."},{"issue":"4","key":"10.1016\/j.gore.2025.102017_b0120","doi-asserted-by":"crossref","first-page":"770","DOI":"10.3390\/cancers16040770","article-title":"Recent Therapeutic advances in Gynecologic Oncology: a Review","volume":"16","author":"Wilson","year":"2024","journal-title":"Cancers"},{"issue":"14","key":"10.1016\/j.gore.2025.102017_b0125","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1001\/jama.2011.1456","article-title":"Association of BRCA1 and BRCA2 Mutations with Survival, Chemotherapy Sensitivity, and Gene Mutator Phenotype in patients with Ovarian Cancer","volume":"306","author":"Yang","year":"2011","journal-title":"J. Am. Med. Assoc."},{"issue":"1","key":"10.1016\/j.gore.2025.102017_b0130","doi-asserted-by":"crossref","first-page":"e6840","DOI":"10.1002\/cam4.6840","article-title":"Desensitization in patients with hypersensitivity to platinum and taxane in gynecological cancers","volume":"13","author":"Zwimpfer","year":"2024","journal-title":"Cancer Med."}],"container-title":["Gynecologic Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S235257892500342X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S235257892500342X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T23:31:58Z","timestamp":1773963118000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S235257892500342X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":26,"alternative-id":["S235257892500342X"],"URL":"https:\/\/doi.org\/10.1016\/j.gore.2025.102017","relation":{},"ISSN":["2352-5789"],"issn-type":[{"value":"2352-5789","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of carboplatin desensitization therapy on progression-free survival in gynecologic cancers","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gore.2025.102017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102017"}}